Royalty Pharma
RPRX
RPRX
333 hedge funds and large institutions have $10.9B invested in Royalty Pharma in 2023 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 143 increasing their positions, 98 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
333
Holders Change
-2
Holders Change %
-0.6%
% of All Funds
5.33%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.16%
New
46
Increased
143
Reduced
98
Closed
43
Calls
$37.9M
Puts
$3.16M
Net Calls
+$34.7M
Net Calls Change
-$4.19M
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
$1.37B |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
$682M |
| 3 |
Swedbank
Stockholm,
Sweden
|
$110M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
$404M |
| 5 |
Goldman Sachs
New York
|
$83M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
$1.44B |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
$1.88M |
| 3 |
Invesco
Atlanta,
Georgia
|
$25.7M |
| 4 |
Morgan Stanley
New York
|
$1.71B |
| 5 |
HSBC Holdings
London,
United Kingdom
|
$906K |
